SCHEMBL4748855

SCHEMBL4748855

CSc1nc(-c2ccccc2)nc(N2CCNCC2)c1C#N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 3/20 0.54
POLB P06746 1/20 0.54
HTT P42858 1/20 0.54
RAB9A P51151 1/20 0.54
TP53 P04637 4/20 0.52
CYP1A2 P05177 4/20 0.52
CYP3A4 P08684 4/20 0.52
CYP2D6 P10635 4/20 0.52
LMNA P02545 2/20 0.52
KDM4E B2RXH2 6/20 0.51
HPGD P15428 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
TSHR P16473 4/20 0.47
USP2 O75604 1/20 0.47
MAPT P10636 1/20 0.46
CYP2C19 P33261 1/20 0.46
KMT2A Q03164 2/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 4/20 0.44
PRKCI P41743 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4744379 0.86 ALDH1A1 (0.50) NPSR1POLBHTTRAB9ATP53
SCHEMBL4787255 0.86 KDM4E (0.70) NPSR1POLBHTTRAB9ATP53
SCHEMBL4745253 0.82 HTT (0.53) NPSR1POLBHTTRAB9ATP53
SCHEMBL7901615 0.79 TP53 (0.49) TP53CYP1A2CYP3A4CYP2D6LMNA
SCHEMBL4747988 0.78 POLB (0.48) NPSR1POLBHTTRAB9ATP53
SCHEMBL8378165 0.76 POLB (0.51) NPSR1POLBHTTRAB9ATP53
SCHEMBL4814396 0.75 POLB (0.45) NPSR1POLBHTTRAB9ATP53
SCHEMBL14070105 0.74 LMNA (0.58) NPSR1POLBHTTRAB9ACYP1A2
SCHEMBL4787080 0.74 LMNA (0.50) NPSR1POLBHTTRAB9ATP53
SCHEMBL4786505 0.73 KDM4E (0.53) NPSR1HTTLMNAKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008110891-A2 NEW HETEROCYCLIC COMPOUNDS ORCHID RESEARCH LABORATORIES LIMITED, (IN) 2008-09-18 WO claimed
US-20080221103-A1 New heterocyclic compounds ORCHID RESEARCH LABORATORIES LTD. (IN) 2008-09-11 US claimed
WO-2008110891-A2 NEW HETEROCYCLIC COMPOUNDS ORCHID RESEARCH LABORATORIES LIMITED, (IN) 2008-09-18 WO disclosed
WO-2008110891-A2 NEW HETEROCYCLIC COMPOUNDS ORCHID RESEARCH LABORATORIES LIMITED, (IN) 2008-09-18 WO disclosed
US-20080221103-A1 New heterocyclic compounds ORCHID RESEARCH LABORATORIES LTD. (IN) 2008-09-11 US disclosed
US-20080221103-A1 New heterocyclic compounds ORCHID RESEARCH LABORATORIES LTD. (IN) 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221103-A1 New heterocyclic compounds LOXL4, CXCR4, LTC4S NPSR1 992/4885POLB 1555/4885HTT 4645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.